DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/zstv7m/amyloidosis) has announced the addition of the "Amyloidosis - Pipeline Review, H1 2015" report to their offering.
This report provides comprehensive information on the therapeutic development for Amyloidosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Amyloidosis and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Companies Involved in Therapeutics Development
- Alnylam Pharmaceuticals, Inc.
- Arcturus Therapeutics, Inc
- Auven Therapeutics Management L.L.L.P
- Bellus Health Inc.
- Celgene Corporation
- GlaxoSmithKline plc
- Immune System Therapeutics Ltd.
- Isis Pharmaceuticals, Inc.
- NeuroPhage Pharmaceuticals, Inc.
- Onyx Pharmaceuticals, Inc.
- Pfizer Inc.
- ProteoTech, Inc.
- Prothena Corporation plc
- SOM Innovation Biotech SL
- Takeda Oncology
- Antisense Oligonucleotide for Transthyretin Amyloidosis
- eprodisate disodium
- GSK-2315698 + GSK-2398852
- ixazomib citrate
- Monoclonal Antibody for Amyloidosis
- Monoclonal Antibody to Inhibit ATTR for Familial Amyloid Polyneuropathy
- RNAi Oligonucleotides to Inhibit Amyloid Precursor Protein for Amyloidosis
- Small Molecule for AL Amyloidosis
- Small Molecules to Inhibit Transthyretin for Familial Amyloid Polyneuropathy
- Small Molecules to Inhibit Transthyretin Related Amyloid Protein for Familial Amyloidotic Cardiomyopathy
- Small Molecules to Inhibit Transthyretin Related Amyloid Protein for Familial Amyloidotic Polyneuropathy
- tafamidis meglumine
For more information visit http://www.researchandmarkets.com/research/zstv7m/amyloidosis